keyword
MENU ▼
Read by QxMD icon Read
search

Urate

keyword
https://www.readbyqxmd.com/read/29780394/monosodium-urate-crystals-activate-the-inflammasome-in-primary-progressive-multiple-sclerosis
#1
Federica Piancone, Marina Saresella, Ivana Marventano, Francesca La Rosa, Maria Antonia Santangelo, Domenico Caputo, Laura Mendozzi, Marco Rovaris, Mario Clerici
Inflammasome-driven inflammation is postulated to play a role in multiple sclerosis (MS), but there is no direct evidence that the nod-like receptor protein 3 (NLRP3) inflammasome is involved in MS pathogenesis. Uric acid was shown to be one of the "danger" signals involved in the activation of NLRP3 inflammasome; notably, the concentration of uric acid is increased in the serum and in the cerebrospinal fluid of MS individuals. To better investigate the role of the NLRP3 inflammasome in MS-associated inflammation, we primed with lipopolysaccharide and stimulated with monosodium urate crystals PBMCs of 41 MS patients with different disease phenotypes...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29777313/gold-nanocluster-based-ratiometric-fluorescent-probes-for-hydrogen-peroxide-and-enzymatic-sensing-of-uric-acid
#2
Dongqin Yang, Minchuan Luo, Junwei Di, Yifeng Tu, Jilin Yan
A method is described for ratiometric fluorometric assays of H2 O2  by using two probes that have distinct response profiles. Under the catalytic action of ferrous ion, the 615 nm emission of protein-stabilized gold nanoclusters (under 365 nm photoexcitation) is quenched by H2 O2 , while an increased signal is generated with a peak at 450 nm by oxidizing coumarin with the H2 O2 /Fe(II) system to form a blue emitting fluorophore. These decrease/increase responses give a ratiometric signal. The ratio of the fluorescences at the two peaks are linearly related to the concentration of H2 O2 in the range from 0...
May 18, 2018: Mikrochimica Acta
https://www.readbyqxmd.com/read/29765222/improving-adherence-to-gout-therapy-an-expert-review
#3
REVIEW
Fernando Perez-Ruiz, Giovambattista Desideri
Gout is the most common form of inflammatory arthritis and is a considerable burden to patients and health care systems worldwide. Despite its clinical, economic, and social impact, patient persistence and adherence to prescribed urate-lowering therapies (ULT), ranging from 20% to 70%, is considered to be among the poorest of all chronic conditions. The majority of gout patients consequently receive suboptimal benefits of their prescribed pharmacotherapies. As gout is associated with several comorbidities along with an increased risk of premature mortality, achieving improved outcomes through adherence to ULT is crucial...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29763636/inhibition-of-cox-2-mpges-1-and-5-lox-in-macrophages-by-leonurine-ameliorates-monosodium-urate-crystal-induced-inflammation
#4
Yanzhuo Liu, Chenfan Duan, Honglei Chen, Chenlong Wang, Xiaoxiao Liu, Miao Qiu, Honglin Tang, Feng Zhang, Xiaoyang Zhou, Jing Yang
Cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX) and microsomal prostaglandin E synthase-1 (mPGES-1)-derived eicosanoids play an essential role in human inflammatory disorders. Here, we investigated whether inhibition of COX-2/mPGES-1 and 5-LOX in macrophages by leonurine ameliorates monosodium urate (MSU) crystal-induced inflammation. Virtual screening assay and in vitro enzyme inhibition assay showed that leonurine was a potential inhibitor of COX-2, mPGES-1 and 5-LOX. Compared with COX-2 inhibitor celecoxib, leonurine (30 mg/kg) significantly decreased ankle perimeter, gait score and neutrophil number in synovial fluid in MSU crystal-treated rats, accompanied with the decreased expression of COX-2, mPGES-1 and 5-LOX and production of prostaglandin E2 (PGE2 ) and leukotriene B4 (LTB4 ) in the synovial fluid macrophages...
May 15, 2018: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/29761242/safety-and-efficacy-of-benzbromarone-and-febuxostat-in-hyperuricemia-patients-with-chronic-kidney-disease-a-prospective-pilot-study
#5
Haibo Yu, Xinying Liu, Yaxiang Song, Jiafen Cheng, Hui Bao, Ling Qin, Xuan Zhou, Ling Wang, Ai Peng
BACKGROUND: To compare the safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with estimated glomerular filtration rate (eGFR) 20-60 mL/min/1.73 m2 . METHODS: This study was a single-centered, parallel-grouped, randomized clinical trial (RCT). We randomly assigned hyperuricemia participants with eGFR 20-60 mL/min/1.73 m2 into benzbromarone and febuxostat treatment group. Drugs were adjusted by titration from small doses. RESULTS: Seventy-three eligible participants enrolled, 66 subjects (33 in each group) were included finally for analysis...
May 14, 2018: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29761226/renal-stone-composition-does-not-affect-the-outcome-of-percutaneous-nephrolithotomy-in-children
#6
Onur Kaygısız, Fethi Ahmet Türegün, Nihat Satar, Ender Özen, Serdar Toksöz, Hasan Serkan Doğan, Mehmet Mesut Pişkin, Volkan İzol, Şaban Sarıkaya, Hakan Kılıçarslan, Tufan Çiçek, Ahmet Öztürk, Serdar Tekgül, Bülent Önal
PURPOSE: We sought to investigate the association between renal stone composition and percutaneous nephrolithotomy outcomes in pediatric patients and define the characterization of the stone composition. METHODS: The data of 1157 children who underwent percutaneous nephrolithotomy between 1991 and 2012 were retrieved from the multicenter database of the Turkish Pediatric Urology Society. The study population comprised 359 children (160 girls, 199 boys) with stone analyses...
May 14, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29759964/risk-of-fragility-fracture-among-patients-with-gout-and-the-effect-of-urate-lowering-therapy
#7
Alyshah Abdul Sultan, Rebecca Whittle, Sara Muller, Edward Roddy, Christian D Mallen, Milica Bucknall, Toby Helliwell, Samantha Hider, Zoe Paskins
BACKGROUND: Previous studies that quantified the risk of fracture among patients with gout and assessed the potential effect of urate-lowering therapy have provided conflicting results. Our study aims to provide better estimates of risk by minimizing the effect of selection bias and confounding on the observed association. METHODS: We used data from the Clinical Practice Research Datalink, which records primary care consultations of patients from across the United Kingdom...
May 14, 2018: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/29759121/diagnosis-and-treatment-of-gout-and-pseudogout-for-everyday-practice
#8
REVIEW
Anthony Sidari, Erica Hill
Gout and pseudogout are crystalline arthropathies commonly seen in primary care. It is important to understand their pathophysiology to facilitate recognition and appropriate treatment. Prompt gouty arthritis treatment relieves short-term suffering. Long-term treatment with urate-lowering therapy prevents recurrent attacks and is generally well-tolerated though flare risk is increased during treatment initiation. When anti-inflammatory medications are prescribed, the flare risk is low. Pseudogout acute treatment is similar to acute gouty arthritis treatment...
June 2018: Primary Care
https://www.readbyqxmd.com/read/29740155/an-update-on-the-genetics-of-hyperuricaemia-and-gout
#9
REVIEW
Tanya J Major, Nicola Dalbeth, Eli A Stahl, Tony R Merriman
A central aspect of the pathogenesis of gout is elevated urate concentrations, which lead to the formation of monosodium urate crystals. The clinical features of gout result from an individual's immune response to these deposited crystals. Genome-wide association studies (GWAS) have confirmed the importance of urate excretion in the control of serum urate levels and the risk of gout and have identified the kidneys, the gut and the liver as sites of urate regulation. The genetic contribution to the progression from hyperuricaemia to gout remains relatively poorly understood, although genes encoding proteins that are involved in the NLRP3 (NOD-, LRR- and pyrin domain-containing 3) inflammasome pathway play a part...
May 8, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29733447/pharmacokinetics-pharmacodynamics-and-tolerability-of-concomitant-multiple-dose-administration-of-verinurad-rdea3170-and-allopurinol-in-adult-male-subjects-with-gout
#10
Martin Kankam, Jesse Hall, Michael Gillen, Xiaojuan Yang, Zancong Shen, Caroline Lee, Sha Liu, Jeffrey N Miner, Susan Walker, Vicki Clauson, David Wilson, Mai Nguyen
Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout. This phase 1b, multiple-dose, drug-drug interaction study evaluated the pharmacokinetics, pharmacodynamics, and tolerability of verinurad in combination with allopurinol. Adult males with gout were randomized to receive once-daily oral doses of allopurinol 300 mg or verinurad 10 mg alone for 7 days, allopurinol 300 mg + verinurad 10 mg on days 8 to 14, and the alternative single agent on days 15 to 21...
May 7, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29733441/the-effect-of-lesinurad-in-combination-with-allopurinol-on-serum-uric-acid-levels-in-patients-with-gout
#11
Scott Baumgartner, Li-Tain Yeh, Zancong Shen, Bradley Kerr, Kimberly Manhard, Barry Quart
The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia. A phase 1b, multicenter, open-label, multiple-dose study was carried out in patients with gout with serum uric acid ≥8 mg/dL following washout of urate-lowering therapy. Patients were treated with allopurinol 300 mg/day alone in week 1; lesinurad 400 or 600 mg/day was added in week 2, followed by lesinurad 400 or 600 mg/day alone in week 3...
May 7, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29725991/retreatment-with-pegloticase-after-a-gap-in-therapy-in-patients-with-gout-a-report-of-four-cases
#12
Allan H Morton, Tony Hosey, Brian LaMoreaux
INTRODUCTION: Pegloticase, a potent uricolytic biologic enzyme, has been shown to be an effective therapeutic option in patients with uncontrolled gout. However, there are limited data on clinical response after a gap in therapy and retreatment with pegloticase. CASE SERIES: This report describes four patients with chronic gout who were successfully managed with pegloticase and were retreated following a gap in therapy. Patient charts from a practice-based rheumatology clinic were retrospectively analyzed; four male patients, aged 70-75 years, with chronic gout and a more than 4-week gap in pegloticase therapy were reviewed...
May 3, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29721712/a-retrospective-analysis-of-medication-prescription-records-for-determining-the-levels-of-compliance-and-persistence-to-urate-lowering-therapy-for-the-treatment-of-gout-and-hyperuricemia-in-the-netherlands
#13
C A Janssen, M A H Oude Voshaar, H E Vonkeman, M Krol, M A F J van de Laar
Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA's Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017...
May 2, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29721694/current-status-of-ultrasound-and-dual-energy-computed-tomography-in-the-evaluation-of-gout
#14
REVIEW
Hillary W Garner, Daniel E Wessell
Gout is the most common inflammatory arthritis and is increasing in relevance due to its rising prevalence and incidence. Dual-energy CT (DECT) and ultrasound (US) are the most frequently used imaging modalities for the diagnosis of gout and for the follow-up of patients receiving therapy. Although DECT has the highest diagnostic accuracy for gout and shows consistently excellent reader agreement in the assessment of urate deposition change after therapy, US also performs well and remains just as important an imaging tool in these realms due to its practical advantages in cost, availability, and safety...
May 2, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29721634/discordant-association-of-the-crebrf-rs373863828-a-allele-with-increased-bmi-and-protection-from-type-2-diabetes-in-m%C3%A4-ori-and-pacific-polynesian-people-living-in-aotearoa-new-zealand
#15
Mohanraj Krishnan, Tanya J Major, Ruth K Topless, Ofa Dewes, Lennex Yu, John M D Thompson, Lesley McCowan, Janak de Zoysa, Lisa K Stamp, Nicola Dalbeth, Jennie Harré Hindmarsh, Nuku Rapana, Ranjan Deka, Winston W H Eng, Daniel E Weeks, Ryan L Minster, Stephen T McGarvey, Satupa'itea Viali, Take Naseri, Muagututi'a Sefuiva Reupena, Phillip Wilcox, David Grattan, Peter R Shepherd, Andrew N Shelling, Rinki Murphy, Tony R Merriman
AIMS/HYPOTHESIS: The A (minor) allele of CREBRF rs373863828 has been associated with increased BMI and reduced risk of type 2 diabetes in the Samoan populations of Samoa and American Samoa. Our aim was to test rs373863828 for associations with BMI and the odds of type 2 diabetes, gout and chronic kidney disease (CKD) in Māori and Pacific (Polynesian) people living in Aotearoa/New Zealand. METHODS: Linear and logistic regression models were used to analyse the association of the A allele of CREBRF rs373863828 with BMI, log-transformed BMI, waist circumference, type 2 diabetes, gout and CKD in 2286 adults...
May 2, 2018: Diabetologia
https://www.readbyqxmd.com/read/29720278/untangling-the-complex-relationships-between-incident-gout-risk-serum-urate-and-its-comorbidities
#16
Mengying Sun, Ana I Vazquez, Richard J Reynolds, Jasvinder A Singh, Mathew Reeves, Tony R Merriman, Angelo L Gaffo, Gustavo de Los Campos
BACKGROUND: Many gout comorbidities (e.g., hypertension) are correlated with serum urate. In this investigation, we identified risk factors (e.g., systolic blood pressure [SBP]), that (1) are associated with incident gout, (2) have effects on gout risk that cannot be fully explained by correlated differences in serum urate, and (3) may modulate the relationship between gout and serum urate. METHODS: Using data from the Atherosclerosis Risk in Communities (ARIC) study, we estimated the unadjusted associations between gout and risk factors by calculating ORs and using chi-square tests...
May 3, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29720269/acidic-preconditioning-of-endothelial-colony-forming-cells-ecfc-promote-vasculogenesis-under-proinflammatory-and-high-glucose-conditions-in-vitro-and-in-vivo
#17
Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Mirta Schattner, Catherine Boisson-Vidal, Soledad Negrotto
BACKGROUND: We have previously demonstrated that acidic preconditioning of human endothelial colony-forming cells (ECFC) increased proliferation, migration, and tubulogenesis in vitro, and increased their regenerative potential in a murine model of hind limb ischemia without baseline disease. We now analyze whether this strategy is also effective under adverse conditions for vasculogenesis, such as the presence of ischemia-related toxic molecules or diabetes, one of the main target diseases for cell therapy due to their well-known healing impairments...
May 2, 2018: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/29720230/urate-inhibits-microglia-activation-to-protect-neurons-in-an-lps-induced-model-of-parkinson-s-disease
#18
Li-Hui Bao, Ya-Nan Zhang, Jian-Nan Zhang, Li Gu, Hui-Min Yang, Yi-Ying Huang, Ning Xia, Hong Zhang
BACKGROUND: Multiple risk factors contribute to the progression of Parkinson's disease, including oxidative stress and neuroinflammation. Epidemiological studies have revealed a link between higher urate level and a lower risk of developing PD. However, the mechanistic basis for this association remains unclear. Urate protects dopaminergic neurons from cell death induced by oxidative stress. Here, we investigated a novel role of urate in microglia activation in a lipopolysaccharide (LPS)-induced PD model...
May 2, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29719791/antihyperuricemic-effect-of-mangiferin-aglycon-derivative-j99745-by-inhibiting-xanthine-oxidase-activity-and-urate-transporter-1-expression-in-mice
#19
Zhizhen Qin, Shoubao Wang, Yihuang Lin, Ying Zhao, Shengqian Yang, Junke Song, Tao Xie, Jinlong Tian, Song Wu, Guanhua Du
A mangiferin aglycon derivative J99745 has been identified as a potent xanthine oxidase (XOD) inhibitor by previous in vitro study. This study aimed to evaluate the hypouricemic effects of J99745 in experimental hyperuricemia mice, and explore the underlying mechanisms. Mice were orally administered 600 mg/kg xanthine once daily for 7 days and intraperitoneally injected 250 mg/kg oxonic acid on the 7th day to induce hyperuricemia. Meanwhile, J99745 (3, 10, and 30 mg/kg), allopurinol (20 mg/kg) or benzbromarone (20 mg/kg) were orally administered to mice for 7 days...
March 2018: Acta Pharmaceutica Sinica. B
https://www.readbyqxmd.com/read/29718730/investigational-drugs-for-hyperuricemia-an-update-on-recent-developments
#20
Tristan Pascart, Pascal Richette
Introduction The significant proportion of gout patients not reaching serum urate levels below 6.0mg/dL and the debated pathogenicity of hyperuricemia (HU) itself motivate investigators to develop new drugs to decrease uricemia. Areas covered This review discusses the drugs considered to be in active development from pre-clinical to phase III studies. This review covers 11 drugs in development, including a xanthine oxidase inhibitor (topiroxostat), uricosurics (verinurad, arhalofenate, UR-1102, tranilast), dual inhibitors (RLBN1001, KUX-1151), a uricase (pergsiticase), an inhibitor of hypoxanthine production (ulodesine), and drugs with yet-to-explain mechanisms of action (levotofisopam, tuna extracts)...
May 2, 2018: Expert Opinion on Investigational Drugs
keyword
keyword
38909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"